Natera president sells $4.1 million in stock By Investing.com

Austin, Texas-Solomon Moskevich, president of Natera Clinical Diagnostics, Inc. (NASDAQ:) recently sold a significant portion of his own holdings in the company. The sale comes as Natera shares have shown remarkable strength, up 159% over the past year. who and the company has a market capitalization of $22.12 billion, according to a filing with the Securities and Exchange Commission, Moskevich Sold 24,861 shares of Natuner common stock, raising approximately $4.1 million, on January 22, 2025. These transactions occurred between $164.95 and $171.95 per share.

After this sale, Moshkevich retains ownership of 140,684 shares in the Company. According to the filing, the sale was made in accordance with the established trading plan related to the reservation of restricted stock units. InvestingPro: The analysis shows that Nata maintains a strong financial position with a “good” health rating and stable liquidity, as evidenced by a current ratio of 4.39. For deeper insights into insider trading patterns and comprehensive financial analysis, investors can access the detailed research report that available exclusively on InvestingPro.

In the latest news, Nata Inc Makes waves in a number of industries. Barclays (London analyst Luc Serchot highlighted Nateri’s evolution from its initial non-NGS-based Nipt focus to becoming a leading player in the Nipp market and its expansion into organ health testing.

Natera has also expanded its patent infringement lawsuit against Neogenomics (NASDAQ: Radar) despite a false advertising lawsuit against the backlash Saving health (NASDAQ:), Natera plans to ask the court to bypass the ruling.In addition, an agreement with executive chairman Dr. Rabinowitz has been amended to allow him to continue in his role under certain conditions.

TD Cowen reaffirmed its buy rating on Natera shares, raising its price target from $175 to $195, reflecting confidence in the company’s future performance.

Finally, Natera reports record Q3 revenue of $439.8 million, up 64% from last year, and conducted 137,000 oncology tests.These latest developments give investors an insight into Natera’s current status and future prospects.

This article is powered by AI and has been reviewed by an editor. See our T&C for more information.